Virtual program

APLAR 2021 | Full Virtual Congressprogram is now available! Scheduled within the (Vietnam) GMT +7 timezone and across a week to ensure that you can attend as many sessions as you want. The Opening Ceremony starts on Saturday 24th October at your local time below:

Japan (JST) 11:45
China (CST) 10:45
India (IST) 08:15
Bangladesh (BST) 08:45
Singapore (SGT) 10:45
Malaysia (MYT) 10:45
Australia (AEDT) 13:45

The below clock also shows you the current time compared to the advertised APLAR program (GMT+7) World Clock

Pre-Congress program

Friday 23 Oct

Friday 23 October
1400-1700	Pre-Congress workshop CH 1 Biomechanics & Movement Workshop with BJC Health Speakers: Errol Lim Managing Director of BJC Health Dr Irwin Lim Consultant Rheumatologist Sarah Comensoli Exercise Physiologist & Manager of Allied Health services Dr Herman Lau Rheumatologist Robyn Yin Head Exercise Physiologist Belinda Price Physiotherapist Blanche Leung Physiotherapist Heidi Kim Physiotherapist Brought to you by

Saturday 24 October
0945 – 1130	CH1: Plenary session 1: Opening Ceremony and Management of rheumatic diseases during the COVID-19 pandemic Chairpersons: Tsutomu Takeuchi and Rohini Handa Speakers COVID-19 in rheumatology practice in Japan Tsutomu Takeuchi, Keio University School of Medicine American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic Ted Mikuls, University of Nebraska RMD and COVID19: The EULAR perspective Robert Landewe, University of Amsterdam
1130 – 1245	CH2: Morning symposium 1 “Beyond remission” based on patients’ subjective experiences for improved RA control Chairpersons: Professor Masayoshi Harigai Professor and Chairperson of Department of rheumatology/Tokyo Women’s Medical University Speakers: Associate Professor Yuko Kaneko Associate Professor, Division of Rheumatology and Department of Internal Medicine/Keio University School of Medicine	CH3: Morning symposium 2 Solving the patient puzzle: A pragmatic approach to SpA management Speakers: Dr Mitsumasa Kishimoto Associate Professor, Department of Nephrology and Rheumatology/Kyorin University School of Medicine Dr Philip Robinson Associate Professor/Brisbane Rheumatology	CH4: Morning symposium 3 New treatment paradigm in RA: Focusing on a novel JAK inhibitor Chairpersons/Speakers: Professor Tatsuya Atsumi Professor of Medicine in the Faculty of Medicine/Hokkaido University Professor Yoshiya Tanaka Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health Professor Tsutomu Takeuchi Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine
	Brought to you by	Brought to you by	Brought to you by
1245 – 1315	Break
1315 – 1445	CH1: Lunch symposium 1 Prospects for JAK inhibitors in the treatment of rheumatoid arthritis Speakers: Dr Kei Ikeda Senior Lecturer, Department of Allergy and Clinical Immunology/Chiba University Hospital Dr Akio Morinobu Department of Rheumatology/Kyoto University Graduate School of Medicine		CH 2: Lunch symposium 2 Basic and Clinical of Rheumatology Chairpersons: Professor Masataka Kuwana Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School Speakers: Professor Yoshiya Tanaka Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health
	Brought to you by		Brought to you by
1445 – 1500	Break
1500 – 1640	CH1: SpA – 1: New advances in Axial Spondyloarthritis	CH2: SLE – 1: Progress and perspectives on SLE in the APLAR region	CH3: Imaging: Imaging in rheumatic diseases – where do we stand	CH4: Treating children with rheumatic diseases in Asia Pacific: The Great Divide
	Chairpersons: Mitsumasa Kishimoto, Katy Leung, Nazrul Islam	Chairpersons: Sandra Navarro and Yoshiya Tanaka	Chairpersons: Chi-Chen Chang and Ved Chaturvedi	Chairpersons: Sumaira Farman and Surjit Singh
	Outcome of Juvenile spondyloarthropathy in adulthood Amita Aggarwal, Sanjay Gandhi Postgraduate Institute of Medical Sciences	Patient education as vital to improving outcomes Laniyati Hamijoyo, University of Padjadjaran	Ultrasound and its clinical use in rheumatoid arthritis Kei Ikeda, Chiba University Hospital	Asia-Pacific Pediatric Rheumatology: Where Do We Stand Sumaira Farman, National Hospital & Medical Center; Al-Aleem Medical College; Fatima Jinnah Medical University
				Improving Access to Care in Resource Challenged Settings: Lessons from the Paediatric Task Force Global MSK Health Helen Foster, Newcastle University
	Treat-to-Target in SpA, how far are we going? James Wei, Chung Shan Medical University Hospital	Progress and Perspectives on SLE in the APLAR region Evan Vista, St. Luke’s Medical Center and College of Medicine	Ultrasound in large vessel vasculitis Kuo-Lung Lai, Taichung Veterans General Hospital	JIA: Geographic variability in treatment and long-term outcomes of JIA Soamarat Vilaiyuk, Mahidol University
	When and how to use, or not to use MRI in SpA” Ashish Jacob Mathew, Christian Medical College	Interim report of the APLAR consensus statements on the management of SLE Chi Chiu Mok, Tuen Mun Hospital	MRI in Rheumatoid Arthritis Mami Tamai, Nagasaki University	Macrophage Activation Syndrome: Analysis of various Cytokines Masaki Shimizu, Tokyo Medcial And Dental University
	Novel assessment tool for bony damage in spondyloarthritis Lai-shan Tam, The Chinese University of Hong Kong	Updates on the Asia Pacific Lupus Collaboration (APLC) cohort Eric Morand	Ultrasound and its clinical use in spondyloarthropathy Lee Ka Wing Gavin	Autoinflammatory disorders: Spectrum seen in Asia Pacific Sulaiman Al-Mayouf, King Faisal Specialist Hospital & Research Center
				Vasculitis: Childhood onset Takayasu arteritis: an update Satish Kumar, Christian Medical College
	Panel Q&A	Panel Q&A	Panel Q&A	Panel Q&A
1640 – 1740	CH1: Abstract session: IgG4-RD, AOSD/sJIA, Kawasaki disease	CH2: Abstract session: SLE and APL syndrome 1	CH3: Abstract session: IIM, SSc, SjS	CH4: Abstract session: COVID-19 and CTD
	Chairperson: TBA	Chairperson: Sandra Navarro	Chairperson: Yeong-Wook Song	Chairperson: Rohini Handa
	Increased Human Neutrophil Lipocalin and its Clinical Relevance in Adult-Onset Still’s Disease Ji Li, Peking University International Hospital	Platelet Indices Could Be Simple, Reliable Predictors of Thrombotic Events in Patients with Antiphospholipid Syndrome Yu Shi, Peking Union Medical College	Clinical and swallowing outcomes in patients with dermatomyositis and polymyositis with dysphagia using the Food Intake LEVEL Scale Shin-ichiro Ohmura, Seirei Hamamatsu General Hospital	Rheumatic diseases on COVID-19 era Selma Abdellaoui, Beni Messous Hospital
	Different Immunophenotypes Characterized IgG4-Related Disease Clinical Phenotypes Eduardo Martín-Nares, Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán	SLE Disease Activity Score (SLE-DAS) is a comparable disease activity measure to SLEDAI-2K Masanori Kono, University of Tokyo Hospital	Immunomodulatory Therapy: a New Strategy for Dermatomyositis /Polymyositis Shengxiao Zhang, The Second Hospital of Shanxi Medical University	Prevalence of emotional disorder and sleep quality in patients with systemic lupus erythematosus during COVID-19 epidemic: a cross-sectional study Jing Zhu, Sichuan Provincial People’s Hospital
	Abnormality of peripheral lymphocyte subsets in patients with Bechet’s disease and their restorations after receiving new immunomodulatory therapy Shengxiao Zhang, The Second Hospital of Shanxi Medical University	Development of a genetic risk score for Filipino patients with systemic lupus erythematosus Michael Tee, University of The Philippines	Characteristics And Outcomes Of Overlap Myositis: A Comparative Multigroup Study In Adults And Children with Idiopathic Inflammatory Myopathies (IIM) Naveen R, Sanjay Gandhi Post Graduate Institute Of Medical Sciences	Factors associated with use of telemedicine for follow-up of lupus nepthritis in the COVID-19 outbreak Ho So, The Chinese University of Hong Kong
	Application Of Preliminary PRINTO Classification Criteria For SJIA In An Indian Cohort Devang Pandya, Dev Children’s Hospital	The Association between Serum Leptin Levels, Body Mass Index, and Disease Activity in Women with Systemic Lupus Erythematosus Nittayawadee Aeamsaard, Phramongkutklao Hospital and College of Medicine	Prognosis and Treatments of Patients with Myositis-associated Severe Interstitial Lung Disease: A Descriptive Study using National Inpatient Database in Japan Hiroki Furuya, Chiba University Hospital	Spectrum Of Systemic Inflammatory Syndrome In Children During COVID 19 Pandemic In India Devang Pandya, Dev Children’s Hospital
	Long-term outcome of 21 cases of giant coronary aneurysm after Kawasaki disease – Our 40 years’ experience Tomomi Sato, Shiga University of Medical Science	Joint Q&A	Nailfold Capillary Changes in Patients with Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Dermatomyositis Tomohiro Sugimoto, Hiroshima University Hospital	Reactive arthritis after COVID-19 infection Keisuke Ono, Kyorin University School of Medicine
	Immunophenotypic analysis of peripheral blood mononuclear cells in IgG4-Related Disease Aya Nishiwaki, The University of Tokyo		Is Rituximab an Adequate Glucocorticoid-Sparing Agent in Idiopathic Inflammatory Myopathies? Bugra Han Egeli	A Healthy Dose of Skepticism: Eosinophilic Granulomatosis with Polyangiitis Initially Presenting as Possible COVID-19 Vincent Anthony Tang, University Of The Philippines – Philippine General Hospital
	Joint Q&A		Joint Q&A	Assessing the Impact on Heath Seeking Behavior During COVID-19 Outbreak in a Group of Rheumatology Patients from Sri Lanka Sunith Atukorale, Ministry of Health
	Joint Q&A		Joint Q&A	Joint Q&A
1740 – 1840	CH1: Evening symposium 1 Management of RA in 2020: is remission achievable and where do JAKs fit? Speakers: Professor Gerd-Rüdiger Burmester Medicine Director of the department of Rheumatology Associate Professor Peter Nash Department of Medicine/University of Queensland, Brisbane, AUSTRALIA	CH2: Evening symposium 2 Treat-to-target in SLE: addressing short- and long-term treatment goals Chariperson: Professor Yoshiya Tanaka Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health Speakers: Professor Yoshiya Tanaka Professor and Chairman of the First Department of Internal Medicine/School of Medicine, University of Occupational and Environmental Health Professor Ian Bruce National Institute of Health Research (NIHR) Senior Investigator and Professor of Rheumatology/University of Manchester Professor Nancy Agmon-Levin Consultant/Tel Aviv and Chaim Sheba Medical Center	CH3: Evening symposium 3 ILD in Focus: Time to prioritize the lung in CTDs Chairperson: Professor Masataka Kuwana Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School Speakers: Professor Masataka Kuwana Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence/Nippon Medical School Professor Yannick Allanore Professor of Rheumatology/University of Paris Professor Marco Matucci-Cerinic Professor of Rheumatology and Medicine at the Department of Experimental and Clinical Medicine/Careggi University Hospital of Florence	CH4: Evening symposium 4 Perspectives around the accumulated evidence for IL-6 in autoimmune disease Chairpersons/Speakers: Dr Kunihiro Yamaoka Division of Rheumatology, Kitasato University Hospital, Japan Dr Shinsuke Yasuda Tokyo Medical and Dental University, Department of Rheumatology, Japan
	Brought to you by	Brought to you by	Brought to you by	Brought to you by

Sunday 25 October
1000 – 1130	CH1: Plenary session 2: Past, present and future of rheumatology Chairpersons: Syed Atiqul Haq and Yoshiya Tanaka Speakers: Rheumatology: A Crystal Gaze? – a future perspective Syed Atiqul Haq, BSM Medical University Two decades of progress in rheumatology – what have we learnt? Iain McInnes, University of Glasgow
1130 – 1245	CH2: Morning symposium 5 Treatment of Rheumatoid Arthritis: Past and Future Speakers: Masaru Kato Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University	CH3: Morning symposium 6 To continue, taper or discontinue biologics – Implications on RA treatment outcomes Chairpersons: Professor Yoshiya Tanaka University of Occupational and Environmental Health, Kitakyushu, JAPAN Speakers: Associate Professor Peter Nash Department of Medicine / University of Queensland, Brisbane, AUSTRALIA Associate Professor Khoa Dinh Nguyen Cho Ray Hospital, Ho Chi Minh City, VIETNAM Professor Wen-Chan Tsai Kaohsiung Medical University Hospital, Kaohsiung, TAIWAN	CH4: Morning symposium 7 Denosumab, anti-RANKL antibody, for the treatment of joint destruction in RA. − From DRIVE & DESIRABLE studies Chairpersons: Professor Tatsuya Atsumi Professor of Medicine in the Faculty of Medicine / Hokkaido University Speakers: Professor Tsutomu Takeuchi Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine
	Brought to you by	Brought to you by	Brought to you by
1245 – 1315	Break
1315 – 1445	CH1: Lunch symposium 3 New insights for clinical practice in Spondyloarthritis, SpA Chairpersons: Associate Professor Yuko Kaneko Associate Professor, Division of Rheumatology and Department of Internal Medicine/Keio University School of Medicine Professor Naoto Tamura Professor and Chairman, Department of Internal Medicine and Rheumatology/Juntendo University School of Medicine Speakers: Dr Kei Ikeda Senior Lecturer, Department of Allergy and Clinical Immunology/Chiba University Hospital Dr Kenta Misaki Chief Director, Department of Rheumatology/Kita-Harima Medical Center Professor Yuho Kadono Chief Administrator, Orthopedic Surgery/Saitama Medical University Brought to you by		CH2: Lunch symposium 4 Innovative therapeutic alternatives for RA, PsA, AS and nr-axSpA: Individualising the treatment approach Chairperson: Dr Kunihiro Yamaoka Division of Rheumatology, Kitasato University Hospital, Japan Speakers: Dr Kunihiro Yamaoka Division of Rheumatology, Kitasato University Hospital, Japan Professor Lars Erik Kristensen Parker Institute / University Copenhagen Professor Andrew Ostör Cabrini Medical Centre / Emeritus Research Brought to you by
1445 – 1500	Break
1500 – 1640	CH1: Merge of Basic and Clinical research in Vascultic disorders	CH2: SLE – 2: SLE clinical	CH3: Genetics: recent progress in genetics of rheumatic diseases	CH4: SpA – 2: Updates in PsA
	Chairpersons: Debashish Danda, Xinping Tian and Masayoshi Harigai	Chairpersons: Yoshiya Tanaka	Chairpersons: Michael Tee and Zhanghou Li	Chairpersons: Atimichi Morita and James Wei
	Section 1: Update on vasculitis	Chairpersons: Yoshiya Tanaka	Chairpersons: Michael Tee and Zhanghou Li	Chairpersons: Atimichi Morita and James Wei
	Recent advances in AAV Tony Sammel, Prince of Wales and Sydney Eye Hospitals	Management of systemic lupus erythematosus (SLE) during and beyond the COVID-19 pandemic Sandra V. Navarra, University of Santo Tomas	GWAS, eQTL and epigenome of rheumatic diseases Kazuhiko Yamamoto, RIKEN Center for Integrative Medical Sciences	Differential diagnosis of Psoriatic arthritis in daily practice Mitsumasa Kishimoto, Kyorin University School of Medicine
	Behcet’s disease – what is new? Thurayya Arayssi, Weill Cornell Medicine
	Genetic analysis of Takayasu arteritis Ruchika Goel, Christian Medical College
	Panel Q&A	Continuing challenges in lupus nephritis Daniel TM Chan, University of Hong Kong	Genetics of Kawasaki Disease: where are we in circa 2020 Surjit Singh, Advanced Pediatrics Centre, Post Graduate Institute of Medical Education And Research, Chandigarh	Risk assessment and prevention of cardiovascular co-morbidities in psoriatic arthritis Lai-Shan Tam, The Chinese University of Hong Kong
	Section 2: APLAR Vascuilitis clinic – recent trends
	Evaluation of large vessel vasculitis Takahiko Sugihara, Tokyo Medical and Dental University
	New trials with repurposed drugs in Takayasu arteritis Xinping Tian, Peking Union Medical College Hospital
	GCA and PMR in Australia: evolving treatment paradigms and clinical research David Liew, Austin Health	Special issues on pregnancy and lactation Aisha Lateef, Woodlands Health Campus	Genetic risk score Sarah Reid	Biomarker for PsA – myth or reality Katy Leung, Singapore General Hospital, Duke-nus Medical School
	Current key areas in futuristic ‘state of the art’ vasculitis research Masayoshi Harigai, Tokyo Women’s Medical University			Treatment update of PsA Peter Nash, Griffith University
	Panel Q&A
	SECTION 3: Beginners research on vasculitic diseases
	Panel discussion by young researchers Carotid Doppler in Takayasu Arteritis Kyaw Thura Zaw GCA research in Adelaide Jem Ninan Suggestions on research in resource limited set up Debashish Danda	Panel Q&A	Panel Q&A	Panel Q&A
1640 – 1740	CH1: Abstract session: IIM, SSc, SjS	CH2: Abstract session: SLE and APL syndrome 2	CH3: Abstract session: OA and Crystal induced arthritis	CH4: Abstract session: SpA, AS-1
	Chairperson: Layla Kazkaz	Chairperson: Yoshiya Tanaka	Chairperson: TBA	Chairperson: Mitsumasa Kishimoto
	Clinical Responses to Low-dose Interleukin-2 in Idiopathic Inflammatory Myopathies Miao Miao, Peking University People’s Hospital	Leukocyte immunoglobulin-like receptor A3 (LILRA3) promotes lupus-like disease severity Yundi Tang, Peking University People’s Hospital	The numeral changes of peripheral lymphocyte subsets in 238 patients with GOUT and their correlation analysis with disease activity Lijun Zhao, The Second Hospital of Shanxi Medical University	Efficacy and Safety of Brodalumab, Anti-IL-17 Receptor A Monoclonal Antibody, for Axial Spondyloarthritis, A 68-Week Result of Phase 3 Study James Wei
	Prediction of myocardial abnormalities in systemic sclerosis, assessed in cardiac magnetic resonance imaging, by using artificial neural networks models Masaki Haraoka, St. Marianna University School of Medicine	Should ophthalmologic evaluation be done as a screening test for new onset lupus patients with no eye complaint? Seyedeh Tahereh Faezi, Tehran University of Medical Sciences	Subtype Genome-Wide Meta-Analyses of Clinically-Defined Gout Revealed Multiple Subtype-Specific Gout Loci and Enrichment of Selection Pressure on ABCG2 and ALDH2 Yusuke Kawamura, National Defense Medical College	Improvements in Patient-Reported Outcomes in AS Patients Treated With Golimumab: Sub-Analysis of Asian Patients Enrolled in Phase III Clinical Trials Wen-Chan Tsai, Kaohsiung Medical University
	Clinical analysis of dermatomyositis / polymyositis / cancer-associated myositis and related research on peripheral blood CD4 + T lymphocyte subsets Pan-di Zhang, The Second Hospital of Shanxi Medical University	Long-term Remission in Systemic Lupus Erythematosus Alireza Khabbazi, Connective Tissue Diseases Research Center	Systematic Review and Meta-Analysis of the Prevalence of Neuropathic-Like Pain and Pain Sensitisation in People With Knee and Hip Osteoarthritis Luigi Zolio, Alfred Health	Abnormality of peripheral lymphocyte subsets in patients with ankylosing spondylitis and restoration after receiving immunoregulatory combination therapies Shengxiao Zhang, The Second Hospital of Shanxi Medical University
	Diagnostic Accuracy of Salivary Free Light Chain and Immunoglobulin Assays in Primary Sjögren’s Syndrome Pulukool Sandhya, St Stephens Hospital Delhi	Voclosporin Has Demonstrated Efficacy in Asian Patients With Lupus Nephritis Tatsuya Atsumi, Hokkaido University	A Randomised Placebo-controlled Clinical Trial of Curcuma Longa Extract for Treating Symptoms and Effusion-synovitis of Knee Osteoarthritis (CurKOA trial) Benny Samuel Eathakkattu Antony, University of Tasmania	Comorbidity Profiles among patients with Axial Spondyloarthritis Fariz Yahya
	The Artificial Intelligence for the Prediction of Focal Score of Labial Salivary Gland Biopsy in the Diagnosis of Sjogren Syndrome Noboru Kitamura, Nihon University School of Medicine	Newly Diagnosed Lupus Nephritis in Elderly Predicts Good Renal Outcome: a Distinct Disease Subset from Young-onset Lupus Nephritis Kazuoto Hiramoto, Keio University School of Medicine	The Trajectory of Exercise Adherence Over Time and the Effect of Theory-lead Intervention for Knee Osteoarthritis in Elderly Limin Wang, Peking University	Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from C-axSpAnd Philip Robinson, University of Queensland
	Effects of Nintedanib in Asian Patients with Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD): Subgroup Analysis of the SENSCIS Trial Masataka Kuwana, Nippon Medical School	Thrombotic risk assessment in patient with systemic lupus erythematosus: validation of the adjusted-Global Antiphospholipid Syndrome Score (aGAPSS) in Thai patients Wanitcha Chanloung, Chiang Mai University	The Prevalence and Incidence of Symptom Knee Osteoarthritis in the Middle-aged and Elderly: a National Survey from China Limin Wang, Peking University	Imbalance of Th17/Treg In Cardiovascular Diseases of Patients With Ankylosing Spondylitis Tingting Ding, The Second Hospital of Shanxi Medical University
	Joint Q&A	Joint Q&A	Prevalence and Clinical Features of Early-onset Osteoarthritis in a Large Scale Cross-sectional Study Jiajing Peng, Peking University People’s Hospital	Joint Q&A
	Joint Q&A	Joint Q&A	Joint Q&A	Joint Q&A
1740 – 1840	CH1: Evening symposium 5 Addressing Unmet Needs in RA and PsA: The Right Drug for the Right Patient Chairpersons: Professor Tsutomu Takeuchi Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine Speakers: Professor Yoshiya Tanaka Professor and Chairman of the First Department of Internal Medicine / School of Medicine, University of Occupational and Environmental Health Professor Filip Van den Bosch Professor of Rheumatology and Head-of-Clinic, Department of Rheumatology / University Hospital of Ghent University Professor Tsutomu Takeuchi Professor of Rheumatology, Department of Internal Medicine/Keio University School of Medicine		CH2: Evening symposium 6 Evolution of interleukin-6 inhibiting therapies for rheumatoid arthritis Chairpersons: Dr Yutaka Kawahito M.D., Ph.D. Head of the Department of Inflammation and Immunology/Kyoto Prefectural University of Medicine Speakers: Professor Motomu Hashimoto Department of Advanced Medicine for Rheumatic Diseases, Kyoto University.
	Brought to you by		Brought to you by

Post-Congress program

Monday 26 October
1445 – 1615	CH1: Update on challenges in osteoporosis management	CH2: Synovial cell biology	CH3: Abstract session: Pathogenesis, Etiology of RA	CH4: Abstract session: Clinical manifestation of RA
	Chairperson: Lau Tang Ching	Chairperson: Syed Atiqul Haq	Chairperson: Kei Ikeda	Chairperson: Worawit Louthrenoo
	Rheumatoid Arthritis associated osteoporosis and fractures- the Taiwan experience Tien Tsai Cheng, Chang Gung Memorial Hospital	Location, location, location: How the epigenome determines synovial pathology in rheumatoid arthritis Gary Firestein	Anti-drug antibodies (ADA) against anti-CD22 monoclonal antibody SM03 in Chinese patients with Rheumatoid Arthritis Guolin Xu	Pulmonary involvement during rheumatoid arthritis Selma Abdellaoui, Beni Messous Hospital
			The clinical features of peripheral lymphocyte subsets in RA patients and effects of combined immunomodulatory therapy on these cells Shengxiao Zhang, The Second Hospital of Shanxi Medical University	Development and validation of clinical predication model for patient-reported pain among rheumatoid arthritis patients Biyu Shen, Affiliated Hospital 2 of Nantong University
			Aberrant Expression of TLR2 Enhanced CD4+ T Cell Activation and Fatty Acid β Oxidation in Rheumatoid Arthritis Ziran Bai, Dalian Medical University	Investigation of comorbidities affecting disease activity in rheumatoid arthritis: a register-based study Takanori Miura, Kakunodate General Hospital
	Management of aromatase inhibitor related bone loss in breast cancer Lubna Nazir	RA: what we’ve learned from arthroplasty Susan M Goodman	Risk of tuberculosis in patients with rheumatoid arthritis: data from a centralized electronic database in Hong Kong Ho Yin Chung, The University of Hong Kong	Characteristics of difficult-to-treat rheumatoid arthritis Satoshi Takanashi, Keio University School of Medicine
			The Risk of Developing Herpes Zoster Differs among Molecular-Targeted Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis Takumi Muramatsu, Kitasato University School of medicine	Clinical characteristics of 75 patients who developed new tuberculosis in NinJa-registration of Japanese rheumatoid arthritis (RA) patient for 16-years Yasuhiko Yoshinaga, Kurashiki Medical Center
			Exome sequencing of Chinese anti-cyclic-citrullinated-peptide-positive rheumatoid arthritis patients Khai Pang Leong, Tan Tock Seng Hospital	High titer of rheumatoid factor as a critical determinant of difficult-to-treat rheumatoid arthritis: the KURAMA cohort Ryu Watanabe, Kyoto University Graduate School of Medicine
	The role of vitamin D in autoimmune diseases Yeap Swan Sim, Subang Jaya Medical Centre		Utility of Measuring Immunogenicity to Novel Subcutaneous CT-P13 in Active RA Patients: 1-Year Results from a Randomized Controlled Pivotal Trial Dae Hyun Yoo, Korean College of Rheumatology	Segmentation of Tendon for Rheumatoid Arthritis using Deep Learning in Ultrasonography Haruyuki Watanabe, Gunma Prefectural College of Health Sciences
		Ultrasonography in the patients with rheumatoid arthritis treated by biological agents and the corresponding synovial histological findings Asami Abe	A pooled real-world long-term persistence rate of tumor necrosis factor-alpha inhibitors in rheumatic diseases: a nationwide, population-based retrospective cohort study James Wei, Chung Shan Medical University Hospital	Development of algorithm for classification of patients into polymyalgia rheumatica and elderly onset rheumatoid arthritis using musculoskeletal ultrasonography Kana Higashitani, National Hospital Organization Yokohama Medical Center
			Joint Q&A	Do We Need Criteria for Elderly-Onset Rheumatoid Arthritis? Chokan Baimukhamedov, Shymkent Medical Center of Joint Diseases
	Guidance on management of GIOP Julie Yu			Joint Q&A

	Panel Q&A
1615 – 1645	Poster exhibition / viewing

Tuesday 27 October
1445 – 1615	CH1: Remission of RA in the APLAR region	CH2: Crystal: Trends and practices of gout management in the Asia Pacific region	CH3: Abstract session: Basic research	CH4: Abstract session: Clinical practice and patient care
	Chairpersons: Zhanguo Li and Tsutomu Takeuchi	Chairpersons: Paulo Lorenzo and Temy Mok	Chairperson: Nazgul Omurzakova	Chairperson: Binit Vaidya
	Trend of remission and difficult to treat RA in a single center of Japan Yuko Kaneko, Keio University School of Medicine	Current guidelines for the management crystal-induced (Gout) arthritis in the Asia-Pacific Ratih Manuaba, Indonesian Rheumatism Association	M3 muscarinic acetylcholine receptor (M3R) reactive Th17 cells in patients with primary Sjögren’s syndrome Saori Abe, University of Tsukuba	Contribution of ultrasound to the diagnosis of the carpal tunnel syndrom Selma Abdellaoui, Beni Messous Hospital
			Expanding regulatory T cells: a new strategy and therapy for rheumatic patients characterized by abnormalities of peripheral lymphocyte subsets Shengxiao Zhang	Could CD14+/16+ monocyte population be used as a predictor of chronic pain post total knee replacement, adjusting for subclinical fibromyalgia? Sam Shan, Northern Health
			Establishment of iPSc and differentiated endothelial cells of PAH associated with systemic sclerosis ; functional and molecular analysis Yuki Kudo, Hokkaido University	Attitudes of Australians with Inflammatory Arthritis to Biologic Therapy and Biosimilars Alannah Quinlivan, The Queen Elizabeth Hospital
	Management of RA in India Ramya Janardana, St John’s National Academy of Health and Allied Sciences	Gout treatment in Chronic Kidney Diseases Worawit Louthrenoo, Chiang Mai University	N6-methyladenosine-modified Circ_0088194 promotes migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes through miR-766-3p/MMP2 axis Yujie Cai, Southern Medical University	Global, regional, and national burden of low back pain, 1990-2019: a systematic analysis for Global Burden of Disease Study 2019 Dongze Wu, The Third Affiliated Hospital of Sun Yat-Sen University
			Activation of Toll-like Receptor Signaling Pathway in Patients with Primary Sjögren’s Syndrome Associated Thrombocytopenia Revealed by B-Lymphocyte High-Throughput Sequencing Shuo Zhang, Peking Union Medical College Hospital	First Ever Single Center Study Revealing Spectrum Of Rheumatic Diseases In 114 Children From An Indian State Of Gujarat Devang Pandya, Dev Children’s Hospital
			Leptin Promotes the Function of Dendritic Cells via Glycolysis Ziran Bai, Dalian Medical University	Effects of Nintedanib on Patient-Reported Outcomes in Japanese Patients with Progressive Fibrosing Interstitial Lung Diseases: Sub-Analysis of INBUILD Masataka Kuwana, Nippon Medical School
	Rheumatoid arthritis remission in Asia-Pacific area Ru Li	New and emerging therapies in gout Binoy J. Paul, KMCT Medical college	CTLA4 signaling down-regulates Fcγ receptor I expression in circulating monocytes: A potential mechanism of action for RA Ryosuke Fukue, Nippon Medical School of Rheumatology	Clinical course of juvenile-onset hyperuricemia complicated by Down’s syndrome: Close correlation with thyroid dysfunction and high obesity Toshiyuki Kitoh, Aichi Gakuin University
			Metabolic Changes Induced by Anti-Malondialdehyde/acetaldehyde Antibodies Promote Osteoclast Development Koji Sakuraba, National Hospiral Organization Kyushu Medical Center	Prevalence of Computer-Related Musculoskeletal Discomfort among International Islamic University Malaysia (IIUM) Female Students Zaitunnatakh Zamli, International Islamic University Malaysia
	Molecular remission for further understanding of drug response in RA Tsutomu Takeuchi, Keio University School of Medicine		TGFβ1 Suppresses Human RANKL-Induced Osteoclast Differentiation via Downregulation of NFATc1 and RANK Expression Tadahiro Tokunaga, Hiroshima University Hospital	Hydroxychloroquine in Patients with Rheumatic Disease: Analysis of Safety in a Single Centre Cohort Avreena Bhullar, Hospital Selayang
		Panel Q&A	Joint Q&A	Reasons for Discontinuation of Biological Drugs Among Patients with Inflammatory Arthritis in the United Arab Emirates Humeira Badsha
	New remission criteria to achieve better outcome of RA Daniel Aletaha			Joint Q&A

1615 – 1645	Poster exhibition / viewing

Wednesday 28 October
1435 – 1615	CH1: Epidemiology COPCORD	CH2: Scleroderma / Myositis	CH3: Abstract session: Treatment of RA	CH4: Abstract session: PsA
	Chairperson: Arvind Chopra	Chairpersons: Andrea Low, Padmanabha Shenoy and So Ho	Chairperson: Basel Masri	Chairperson: TBA
	The COPCORD Asia Pacific Epidemiology- A Learning For the Future Syed Atiqul Haq, BSM Medical University	New frontiers in the management of ILD in SSc Hyun-Sook Kim, Soonchunhyang University Seoul Hospital	Efficacy of Filgotinib in Patients with Rheumatoid Arthritis with Poor Prognostic Factors: Post Hoc Analysis of FINCH 3 Tatsuya Atsumi, Hokkaido University	Abnormality of peripheral lymphocytes subsets in psoriatic arthritis patients and restoration after receiving new immunoregulatory combination therapies: a cross-sectional study Shengxiao Zhang, The Second Hospital of Shanxi Medical University
			Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with RA: Results at 72 Weeks from the SELECT-COMPARE Study Andrew Oster	Efficacy and Safety of Guselkumab, an anti-IL-23p19 mAb, in Biologic-naïve Patients with Active PsA Through Week-52 of a Phase-3 Study Iain McInnes, University of Glasgow
	Making sense of the existent Phase 1 data Nazrul Islam	Pregnancy outcomes in systemic sclerosis and myositis Latika Gupta, Sanjay Gandhi Postgraduate Institute of Medical Sciences	Effects of Fostamatinib, an Oral Spleen Tyrosine Kinase Inhibitor, in Asian RA Patients With MTX-IR from Phase III Study Yoshiya Tanaka, University of Occupational And Environmental Health	Comparative Efficacy of Guselkumab in Patients with Psoriatic Arthritis: Results from Systematic Literature Review and Network Meta-Analysis Steve Peterson, Janssen Global Services
			A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis Tsutomu Takeuchi, Keio University School of Medicine	Assessment of Nail Bed Thickness by Ultrasound in patients with Psoriatic arthritis and their correlation with Disease activity indices Prajakta Dekate, Hyderabad Rheumatology Center
	Oriental Wisdom on Risk and Causality Ashish Mathews, Christian Medical College	Panel Q&A	Pharmacokinetics, safety and tolerability of otilimab in Japanese patients with active moderate-to-severe rheumatoid arthritis despite treatment with methotrexate Tatsuya Atsumi, Hokkaido University	Guselkumab for Active Psoriatic Arthritis: One-Year Results of a Phase-3, Randomized, Double-Blind, Placebo-Controlled Study of Biologic-Naïve or TNFα Inhibitor-Experienced Patients James Wei, Chung Shan Medical University Hospital
		Updates on the SSc/myositis APLAR collaboration Takahisa Gono, Nippon Medical School Graduate School of Medicine	Certolizumab Pegol in Patients with Rheumatoid Arthritis: Pooled Efficacy Analysis of Phase 3 Clinical Trials across Baseline Rheumatoid Factor Quartiles Yoshiya Tanaka, University of Occupational and Environmental Health	Guselkumab-Treated Patients Achieved Clinically Meaningful Improvement in Systemic Symptoms as Measured with PROMIS Instrument: Results from DISCOVER-1 Psoriatic Arthritis Trial James Wei, Chung Shan Medical University Hospital
			Sustainability of Response to Upadacitinib Alone or In Combination Among Rheumatoid Arthritis Patients with Inadequate Response to Conventional Synthetic DMARDs Peter Nash, Griffith University	Long term association of Streptococcus tonsillitis and subsequent risk of psoriasis: A population-based, big data, cohort analysis Ming-Li Chen, Chung Shan Medical University
	Recent COPCORD Overview Yin Minn Soe Muhammad Ahmed Saeed	Amyopathic Dermatomyositis Associated ILD -the Asian experience – Experience from China Ye Shuang, Shanghai Renji Hospital South Campus	Upadacitinib in Patients with Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological DMARDs: Results at 60 weeks from SELECT-BEYOND Stephen Hall	Efficacy and Safety of Upadacitinib Versus Placebo and Adalimumab in Patients with PsA and Inadequate Response to Non-Biologic DMARDs (SELECT-PsA-1) Mitsumasa Kishimoto, Kyorin University School of Medicine
			Safety Profile of Upadacitinib in Japanese Patients with Rheumatoid Arthritis Kunihiro Yamaoka, Kitasato University School of Medicine	Efficacy and Safety of Upadacitinib in Patients with PsA and Inadequate Response to Biologic DMARDs (SELECT-PsA-2) Shigeyoshi Tsuji, Kyorin University School of Medicine
	APLAR COPCORD – what is missing? Arvind Chopra	The Management of Rapidly Progressive Interstitial Lung Disease Associated with Clinically Amyopathic Dermatomyositis in Japan Shinji Sato, Tokai University School of Medicine	Long-Term Safety and Efficacy of Upadacitinib in Japanese Patients with Rheumatoid Arthritis and Inadequate Response to csDMARDs: Results from SELECT-SUNRISE Hideto Kameda, Toho University (Ohashi Medical Center)	Efficacy of Guselkumab on Axial-Involvement Endpoints in Patients with Active PsA with Imaging-Confirmed Sacroiliitis: Week-24 Results from Two Phase-3 Studies Denis Poddubnyy
	Panel Q&A		Upadacitinib as Monotherapy in Patients with Rheumatoid Arthritis: Results at 48 weeks from the SELECT-MONOTHERAPY Study Yoshiya Tanaka, University of Occupational and Environmental Health	Joint Q&A
		Panel Q&A	Joint Q&A

1615 – 1630	Break
1630 – 1730	Evening symposium 3 ILD in Focus: Time to prioritize the lung in CTDs Chairperson: Professor Masataka Kuwana Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence / Nippon Medical School Speakers: Professor Marco Matucci-Cerinic Professor of Rheumatology and Medicine at the Department of Experimental and Clinical Medicine/Careggi University Hospital of Florence Professor Yannick Allanore Professor of Rheumatology / University of Paris Professor Masataka Kuwana Professor of Allergy and Rheumatology and a director of Scleroderma & myositis center of excellence / Nippon Medical School		Industry symposium
	Brought to you by
1800 – 1830	Poster exhibition / viewing

Thursday 29 October
1320 – 1500	Merge of Basic and Clinical research in Vascultic disorders REPEAT SESSION Section 1: Update on vasculitis disorders Recent advances in AAV Tony Sammel Behcet’s disease – what is new? Thurayya Arayssi Genetic analysis of Takayasu arteritis Ruchika Goel Section 2: APLAR Vasculitis clinic – recent trends Evaluation of large vessel vasculitis Takahiko Sugihara New trials with repurposed drugs in Takayasu arteritis Xinping Tian GCA and PMR in Australia: evolving treatment paradigms and clinical research David Liew Current key areas in futuristic ‘state of the art’ vasculitis research Masayoshi Harigai Section 3: Beginners research on vasculitic diseases Carotid Doppler in Takayasu Arteritis Kyaw Thura Zaw GCA research in Adelaide Jem Ninan Suggestions on research in resource limited set up Debashish Danda
1515 – 1615	CH1: Joint APLAR SIG business meeting	CH2: AYR Symposium: genetics in autoimmune diseases	CH3: Abstract session: SpA, AS-2	CH4: Abstract session: Rheumatoid arthritis
	Chairpersons: Yoshiya Tanaka and Rohini Handa	Chairpersons: Priscilla Wong and Ghita Harifi	Chairperson: Katy Leung	Chairperson: Duminda Munidasa
	Systemic Lupus Erythematosus (SLE) update Yoshiya Tanaka	Genetics in Autoimmune Diseases Made Easy Yukinori Okada	Characteristics of peripheral blood lymphocyte subsets in patients with ankylosing spondylitis Zheng Li, The Second Hospital of Shanxi Medical University	Predictors of serious infections in patients with rheumatoid arthritis receiving bDMARDs or tsDMARDs Ekaterina Koltsova, Research Institute of The Organization of Health and Healthcare Management
	Vasculitis update Debashish Danda		Association of Obesity with Worse Disease Severity and Treatment Response in Ankylosing Spondylitis: Data from the Smart-phone SpondyloArthritis Management System Lidong Hu, Chinese PLA General Hospital	Tofacitinib may have a direct analgesic effect. Data from the Moscow Unified Register of Arthritis (MUAR) Evgeny Zhilyaev, Russian Medical Academy of Continuing Professional Education
	Spondylitis (SPA) update Lai-Shan Tam		Risk of Malignancy and Tuberculosis of Biological and Targeted Drug in Patients with Spondyloarthritis: Systematic Review and Meta-analysis Xiaojian Ji, Chinese Pla General Hospital	Switch from original “Mabtera” to Rituximab Biosimilar BCD-020 in Rheumatoid Arthritis Patients in Real-World Clinical Practice According to MUAR Data Galina Lukina, Moscow Clinical Scientific Center Named After А.s.loginov
	Scleroderma / Myositis update Andrea Low	Pharmacogenetics in Autoimmune Diseases Khai Pang Leong	Randomized Controlled Trial of Oral Corticosteroids in Axial Spondyloarthritis : Modified COBRA regime (COBRA-AS) Debashish Mishra, Pgimer	DAS28 Remission and Low Disease Activity Among Rheumatoid Arthritis Patients in the United Arab Emirates Humeira Badsha
	Osteoporosis update Tan Ching Lau		Secukinumab Improves Signs and Symptoms of Non-radiographic Axial Spondyloarthritis in Patients Naïve to TNF Inhibitor: Results from the PREVENT Study Hideto Kameda, Toho University	Attitudes towards medications in Rheumatoid arthritis patients attending a tertiary care clinic in Sri Lanka Shalini Janagan, National Hospital of Sri Lanka
	Crystal-induced arthritis update Paolo Lorenzo		Treatment-Related Outcomes of Ankylosing Spondylitis Patients Initiating Biologic Therapy in Taiwan – A Population-Based Analysis Chia-Fang Lee, Eli Lilly and Company	Prevalence And Related Factors Of Depression In Rheumatoid Arthritis Patients Hung Nguyen Van
	APLAR COPCORD Epidemiology update Arvind Chopra	Joint Q&A	Joint Q&A	Joint Q&A
	Paediatric Rheumatology update Sumaira Farman
	AYR update Yew-Kuang Cheng
	Panel Q&A
1615 – 1830	Closing Ceremony

#APLAR20

Pre-Congress program

Featured program

Post-Congress program

Organiser